. Author manuscript; available in PMC: 2009 Jan 1.

Published in final edited form as: Biochim Biophys Acta. 2007 Oct 16;1785(1):63–84. doi: 10.1016/j.bbcan.2007.10.003

Table 1.

Summary of five years response in patients remaining on first-line imatinib therapy from the phase III IRIS trial

Parameter	% of patients
Complete hematologic response	97
Major cytogenetic response	89
Complete cytogenetic response	82
Survival Overall Excluding non-CML deaths	89 95
Survival without accelerated or blastic phase	93
Event-free survival	83